Northwest Biotherapeutics (NBYB) Stock Price & Analysis

NBYB Stock Chart & Stats

€0.13-€0.01(-3.70%)

At close: Oct 30 1:00 AM GMT+1

Day’s Range: EUR 0.13 - EUR 0.17
52-Week Range: EUR 0.10 - EUR 0.38
Previous Close: EUR 0.14
Volume: N/A
Average Volume (3M): 25.46K
Market Cap: EUR 259.63M
Enterprise Value: EUR 374.52T
Total Cash (Recent Filing): EUR 595.00K
Total Debt (Recent Filing): EUR 56.44M
Price to Earnings (P/E): ―
Beta: 0.97
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Northwest Biotherapeutics News

Northwest Biotherapeutics Secures New Commercial Loan Financing

An update from Northwest Biotherapeutics ( ($NWBO) ) is now available. On October 26, 2026, Northwest Biotherapeutics entered into a $5.505 million commercial loan agreement with Streeterville Capital, LLC, carrying

3d ago8K NWBO

Northwest Biotherapeutics enters MOU for collaboration with SPIMACO

Northwest Biotherapeutics (NWBO) entered into a non-binding Memorandum of Understanding with the Saudi Pharmaceutical Industries and Medical Appliance Company for a collaboration to bring the Company’s DCVax-L products and technology

2M agoNWBO NBYB

Northwest Biotherapeutics Secures New Convertible Note Financing

Northwest Biotherapeutics ( ($NWBO) ) has provided an update. On July 29, 2026, Northwest Biotherapeutics entered into a $4.9 million 12-month convertible promissory note financing with YA II PN, Ltd.,

3M ago8K NWBO

Northwest Biotherapeutics names Annalisa Jenkins as strategic advisor

Northwest Biotherapeutics (NWBO) announced the appointment of Annalisa Jenkins, M.B.B.S., F.R.C.P., as a Strategic Adviser. Dr. Jenkins brings over 25 years of biopharma leadership, spanning global R&D executive roles at

6M agoNWBO NBYB

Northwest Biotherapeutics establishes dedicated leukapheresis clinic

Northwest Biotherapeutics (NWBO) is establishing its own dedicated clinic for leukapheresis procedures at The London Welbeck Hospital. The Company is doing so in order to proactively address potential constraints in

6M agoNWBO NBYB

Northwest Biotherapeutics Completes Advent BioServices Acquisition Deal

Northwest Biotherapeutics ( ($NWBO) ) has shared an update. On October 24, 2025, Northwest Biotherapeutics, Inc. completed the acquisition of Advent BioServices Ltd., a U.K.-based CDMO that had been providing

6M ago8K NWBO

Northwest Biotherapeutics Delays Annual SEC Filing

Northwest Biotherapeutics ( ($NWBO) ) has released a notification of late filing. Northwest Biotherapeutics, Inc. has filed a Form 12b-25 to notify investors that it will delay its Form 10-K

7M agoNWBO NBYB

Northwest Biotherapeutics Reaches Settlement Over 2020 Stock Options

Northwest Biotherapeutics ( ($NWBO) ) has provided an update. On December 12, 2025, Northwest Biotherapeutics entered into a settlement agreement with lead plaintiff F. Glenn Schaeffer to resolve Delaware Chancery

9M ago8K NWBO

Northwest Biotherapeutics Expands Authorized Common Stock Capacity

Northwest Biotherapeutics ( ($NWBO) ) has issued an announcement. At its annual meeting of stockholders on December 29, 2025, Northwest Biotherapeutics shareholders approved all four proposals on the agenda, including

10M ago8K NWBO

Northwest Biotherapeutics Secures $5M Convertible Note Financing

Northwest Biotherapeutics ( ($NWBO) ) just unveiled an announcement. On November 14, 2025, Northwest Biotherapeutics entered into a $5 million convertible promissory note financing with YA II PN, Ltd., managed

11M ago8K NWBO

Northwest Biotherapeutics Secures $5.5M Loan Agreement

Northwest Biotherapeutics ( ($NWBO) ) just unveiled an update. On October 27, 2025, Northwest Biotherapeutics, Inc. entered into a Commercial Loan Agreement with Streeterville Capital, LLC for $5,505,000. The loan

1y ago8K NWBO

Northwest Biotherapeutics Files New Form S-3 Registration

Northwest Biotherapeutics ( ($NWBO) ) has shared an announcement. On October 23, 2025, Northwest Biotherapeutics filed a new Form S-3 registration statement to replace its existing shelf registration, which was

1y ago8K NWBO

Northwest Biotherapeutics Settles Litigation Over Option Awards

Northwest Biotherapeutics ( ($NWBO) ) has shared an update. Northwest Biotherapeutics has reached a settlement agreement on October 9, 2025, with Lead Plaintiff F. Glenn Schaeffer regarding litigation over option

1y ago8K NWBO

Northwest Biotherapeutics announces passing of general counsel Les Goldman

Northwest Biotherapeutics (NWBO) announced the passing of its Senior Vice President and General Counsel, Les Goldman, due to a stroke. Goldman’s duties are being assumed by other members of the

1y agoNWBO NBYB

NBYB FAQ

What was Northwest Biotherapeutics’s price range in the past 12 months?

Northwest Biotherapeutics lowest stock price was €0.10 and its highest was €0.38 in the past 12 months.

What is Northwest Biotherapeutics’s market cap?

Northwest Biotherapeutics’s market cap is €259.63M.

When is Northwest Biotherapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Northwest Biotherapeutics’s earnings last quarter?

Northwest Biotherapeutics released its earnings results on May 16, 2018. The company reported -€0.078 earnings per share for the quarter.

Is Northwest Biotherapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Northwest Biotherapeutics pay dividends?

Northwest Biotherapeutics does not currently pay dividends.

What is Northwest Biotherapeutics’s EPS estimate?

Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Northwest Biotherapeutics have?

Northwest Biotherapeutics has 1,705,638,000 shares outstanding.

What happened to Northwest Biotherapeutics’s price movement after its last earnings report?

Northwest Biotherapeutics reported an EPS of -€0.078 in its last earnings report. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Northwest Biotherapeutics?

Currently, no hedge funds are holding shares in DE:NBYB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Northwest Biotherapeutics Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.

Northwest Biotherapeutics (NBYB) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	5	3	14
Technical Analysis	5	3	2
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to DE:NBYB
Company	Price & Change	Follow
INOInovio Pharmaceuticals
PDSBPDS Biotechnology
ANIXAnixa Biosciences
GLSIGreenwich LifeSciences
GNLXGenelux Corp.

Compare DE:NBYB Stocks >

Ownership Overview

0.04% Other Institutional Investors
99.96% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NBYB Stock Chart & Stats

Northwest Biotherapeutics News

Northwest Biotherapeutics Secures New Commercial Loan Financing

Northwest Biotherapeutics enters MOU for collaboration with SPIMACO

Northwest Biotherapeutics Secures New Convertible Note Financing

Northwest Biotherapeutics names Annalisa Jenkins as strategic advisor

Northwest Biotherapeutics establishes dedicated leukapheresis clinic

Northwest Biotherapeutics Completes Advent BioServices Acquisition Deal

Northwest Biotherapeutics Delays Annual SEC Filing

Northwest Biotherapeutics Reaches Settlement Over 2020 Stock Options

Northwest Biotherapeutics Expands Authorized Common Stock Capacity

Northwest Biotherapeutics Secures $5M Convertible Note Financing

Northwest Biotherapeutics Secures $5.5M Loan Agreement

Northwest Biotherapeutics Files New Form S-3 Registration

Northwest Biotherapeutics Settles Litigation Over Option Awards

Northwest Biotherapeutics announces passing of general counsel Les Goldman

NBYB FAQ

Northwest Biotherapeutics Stock Smart Score

Company Description

Northwest Biotherapeutics

Northwest Biotherapeutics (NBYB) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium